BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Frontage Labs strengthens early phase clinical capabilities across US and China

February 2, 2026 | News

To support pharmaceutical and biotech partners with accelerated, highÃ¢â?¬â??quality clinical development solutions



Frontage Laboratories, Inc., a global Contract Research, Development and Manufacturing Organization (CRDMO), has announced the expansion of its early phase clinical research capabilities across the United States (US) and China. This strategic growth enhances the company's ability to support pharmaceutical and biotech partners with accelerated, highÃ¢â?¬â??quality clinical development solutions.

Frontage's US operations are anchored by a modern 160Ã¢â?¬â??bed, 36,000Ã¢â?¬â??sqÃ¢â?¬â??ft Phase I clinical unit in Secaucus, New Jersey, designed to conduct largeÃ¢â?¬â??scale Phase I and Bioequivalence (BE) studies as well as radiolabeled human AME research.

The company has further strengthened its C14Ã¢â?¬â??hAME capabilities through a dedicated unit staffed by licensed radiation experts and supported by an onsite nuclear pharmacy for sterile and nonÃ¢â?¬â??sterile radiolabeled compounding. Frontage has successfully executed combined hAME and Absolute Bioavailability studies aligned with the FDA's 2024 guidance.

In response to growing industry demand, Frontage is also expanding into Oncology Phase I trials through partnerships with regional hospitals and clinical networks, enabling patientÃ¢â?¬â??based research across key cancer indications.

As the industry approaches a significant wave of patent expirations, Frontage's multiple US clinical units are positioned to manage complex, highÃ¢â?¬â??volume BE programmes. Collaboration with Frontage China enables flexible MultiÃ¢â?¬â??Regional Clinical Trial (MRCT) execution to support global programme timelines.